Tetratherix delivers breakthrough scar prevention results with TetraDerm
Tetratherix (ASX: TTX) has reported Tetratherix TetraDerm Scar Prevention Results showing average Vancouver Scar Scale (VSS) scores of 1.8/13 at three months, declining to 1.1/13 at 12 months in Cohort 1 patients. On the VSS system, where 0 represents healthy intact skin and 13 indicates highly visible prominent scarred tissue, these results demonstrate that scarring was restricted to just 8% after 12 months in patients with average wound sizes of 5.5cm and up to 9cm. Zero adverse events were observed throughout the cohort, with no seroma formation recorded.
The interim results represent clinical validation for TetraDerm’s preventative approach in a US$2.1 billion addressable wound closure market. All Cohort 1 patients completed their 12-month follow-up assessments, marking completion of the study’s first phase focused on trunk and limb lesion surgeries.
When big ASX news breaks, our subscribers know first
What is the Vancouver Scar Scale and why does it matter?
The Vancouver Scar Scale is the globally recognised standard for measuring scar appearance in clinical settings. VSS assesses four distinct parameters: skin redness (vascularity), pigmentation, tissue hardness (pliability), and scar height relative to surrounding skin. Scores range from 0 to 13, with higher values indicating more prominent scarring.
In the TetraDerm clinical study, measurements were completed by an independent and blinded physician at 6 weeks, 3 months, 6 months, and 12 months following surgery. At six weeks, skin appearance in all patients was recorded as normal. At three months, patients displayed no skin redness and presented scar heights similar to intact skin, with one exception showing increased height of 2mm to 5mm.
TetraDerm’s 1.1/13 result at 12 months indicates surgical sites that are close to healthy, unimpacted skin tissue in both appearance and structural fill. Using an industry-standard measurement system strengthens the clinical evidence package for regulatory submissions and commercial partner evaluations.
How TetraDerm works to prevent scars before they form
TetraDerm represents a fundamental shift from treating existing scars to preventing their formation during surgery. The product is delivered to physicians as a liquid in a ready-to-use syringe and applied by surgeons immediately before final suturing.
Current scar-management solutions, including silicone treatments, lasers, and complex biologics, are applied after scars have already formed. These approaches often deliver limited clinical benefit or present accessibility challenges for patients. TetraDerm addresses the underlying biological mechanisms during the surgical procedure itself.
The product’s three-step mechanism of action operates as follows:
- Dead space elimination: TetraDerm fills the tissue bed, occupying gaps between tissue layers that would otherwise accumulate excess fluid.
- Seroma control: The gel absorbs excess fluid at the surgical site, preventing the formation of seroma (fluid retention that interferes with natural healing).
- Tension reduction: By providing structural support, TetraDerm reduces mechanical tension at the incision site that contributes to visible scarring.
Once applied, TetraDerm transforms using the patient’s own body heat from a liquid into a cohesive, elastic, and adhesive gel. This transformation allows the material to integrate with the wound environment and support natural healing processes. The product is formulated from Tetratherix’s proprietary Tetramatrix™ platform technology.
TetraDerm is not a dermal substitute and is not intended for burns or skin grafting applications. The product is specifically designed for surgical incision sites, representing a distinct clinical use case focused on reducing scar formation in elective and emergency surgeries.
Clinical applications and market opportunity
TetraDerm has applicability across high-volume surgical procedures where incisions through skin tissue require suturing. Key target procedures include joint replacement surgery, caesarean section, and skin tumour removal. These procedures alone represent approximately 5 million cases annually in the United States and 12 million procedures globally per year.
Scarring carries consequences beyond aesthetic concerns. Scar tissue can cause redness, pigmentation changes, and raised stiff tissue that restricts movement. When scarring forms between skin layers and bone, it can collect and compress nerve endings, resulting in pain, discomfort, and reduced function at the surgical site. Minimising scar formation supports better clinical and functional outcomes for patients.
TetraDerm’s commercial advantages include seamless integration into existing clinical workflows, no requirement for additional equipment or hospital infrastructure, and cost-effective application. The product fits within established surgical protocols without necessitating staff retraining or capital expenditure on new technology platforms.
| Surgical Application | US Annual Procedures | Global Annual Procedures |
|---|---|---|
| Joint replacement surgery | ~1.7 million | ~4 million |
| Caesarean section | ~1.2 million | ~3.5 million |
| Skin tumour removal | ~2.1 million | ~4.5 million |
| Total addressable market | ~5 million | ~12 million |
Based on Tetratherix’s internal modelling, this market represents a US$2.1 billion total addressable opportunity. The large procedural volumes and straightforward hospital adoption pathway support a scalable commercial model with potential for rapid market penetration following regulatory clearance.
Study progress and pathway to commercialisation
The TetraDerm clinical study comprises three cohorts designed to assess scar prevention across different surgical contexts. Each cohort follows patients for 12 months post-surgery with regular VSS assessments by independent, blinded physicians.
Current study status by cohort:
- Cohort 1 (trunk and limb lesions): Complete, with all patient 12-month follow-ups finished. This cohort assessed incision sites with average wound sizes of 5.5cm and up to 9cm.
- Cohort 2 (face and neck lesions): Past midpoint enrolment, with patients having passed the six-month safety review timepoint. This cohort targets the aesthetically sensitive facial region where scar prevention carries particular clinical value.
- Cohort 3 (complex plastic and reconstructive surgeries): Recruitment commenced in January 2026. This final cohort addresses more challenging surgical scenarios with higher baseline scar formation risk.
The successful completion of Cohort 1 enabled progression to Cohort 3 recruitment following the six-month safety review of Cohort 2 patients. Regulatory approval for TetraDerm is proceeding on the timeline disclosed in the company’s prospectus.
Tetratherix’s commercial model centres on securing an exclusive global partnership with a leader in the surgical consumable market. The company has already commenced engagement discussions with potential commercial partners and continues its business development process alongside comprehensive due diligence on multiple candidates. The strengthening clinical validation package following these Cohort 1 results positions the company to advance partnership negotiations.
CEO commentary on clinical validation
Will Knox, CEO
“It’s one thing to theorise about tissue architecture, it’s quite another to fundamentally disrupt the inevitability of scarring. What we are seeing with TetraDerm is a paradigm shift from treating pathology to preventing it. Achieving an average VSS score as low as 1.1 out of 13 at the twelve-month mark is, frankly, an extraordinary validation of our deliberate design, both commercially as well as clinically. It proves that our technology doesn’t just ‘manage’ a wound, it integrates with human healing to preserve the integrity of the skin.”
Knox emphasised the execution velocity distinguishing Tetratherix’s development pathway. With recruitment underway for the final cohort targeting complex reconstructive surgeries, the company is systematically de-risking a substantial commercial opportunity in the US$2.1 billion wound closure market. The CEO stated the company is focused on establishing a new global standard in surgical outcomes rather than pursuing niche applications.
The next major ASX story will hit our subscribers first
What this means for Tetratherix investors
The Tetratherix TetraDerm Scar Prevention Results strengthen the investment case by providing clinical validation of the product’s preventative mechanism. Achieving average VSS scores of 1.1/13 at 12 months with zero adverse events de-risks the regulatory pathway and enhances the company’s negotiating position with potential global commercial partners.
With Cohort 1 complete and Cohorts 2 and 3 progressing on schedule, Tetratherix is building the clinical evidence package required to support partnership discussions and regulatory submissions. The large addressable market combined with TetraDerm’s differentiated prevention-focused approach creates substantial revenue potential in a sector where existing solutions primarily address scars after formation.
Near-term catalysts for shareholders to monitor include:
- Cohort 2 data readout: Face and neck lesion results will demonstrate TetraDerm’s performance in aesthetically critical surgical sites where scar visibility carries heightened patient and physician concern.
- Cohort 3 enrolment completion: Progress in recruiting complex reconstructive surgery patients will indicate timeline to final dataset.
- Partnership announcements: Commercial partner selection represents a material value inflection point, given the exclusive global rights structure outlined in the company’s commercial model.
- Regulatory milestone progress: Updates on approval timelines across key markets will clarify commercialisation pathways and revenue generation timing.
The systematic cohort completion approach provides multiple data readout opportunities throughout 2026, maintaining newsflow visibility as the company progresses toward commercial launch discussions.
Get Healthcare Breakthroughs Before the Market Moves
Join 20,000+ investors receiving FREE ASX healthcare news and analysis within minutes of release. Big News Blast delivers breaking announcements with expert coverage the moment they hit the market. Click the “Free Alerts” button to start receiving real-time alerts on the next potential healthcare breakthrough.